Business NewsPR NewsWire • Biopharmaceutical M&A expected to soar in 2017 as pricing pressures dim global revenue outlook

Biopharmaceutical M&A expected to soar in 2017 as pricing pressures dim global revenue outlook

Biopharmaceutical M&A expected to soar in 2017 as pricing pressures dim global revenue outlook

SAN FRANCISCO, Jan. 9, 2017 /PRNewswire/ -- The biopharmaceutical industry's desire for inorganic growth is expected to intensify an already heated mergers and acquisitions (M&A) environment in 2017. This is according to the EY M&A Outlook and Firepower Report 2017 that was...

View More : http://www.prnewswire.com/news-releases/biopharmaceutical-ma-expected-to-soar-in-2017-as-pricing-pressures-dim-global-re...
Releted News by prnewswire
Nissan Titan Wins TRUCK TREND'S 2017 Pickup Truck of the Year Award
AcelRx Pharmaceuticals Provides Guidance on 2017 Milestones for ARX-04, now known as DSUVIA™ in the United States, for the Treatment of Moderate-to-Severe Acute Pain
LIMA Inks Exclusive Partnership with UBM for Licensing Expo China
Biopharmaceutical M&A expected to soar in 2017 as pricing pressures dim global revenue outlook
CompTIA to Launch IT Pro Association to Help Foster Skilled Workforce